153 related articles for article (PubMed ID: 36586583)
1. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis.
Leung DYM; Paller AS; Zaenglein AL; Tom WL; Ong PY; Venturanza ME; Kuligowski ME; Li Q; Gong X; Lee MS
Ann Allergy Asthma Immunol; 2023 Apr; 130(4):500-507.e3. PubMed ID: 36586583
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
[TBL] [Abstract][Full Text] [Related]
3. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
Bissonnette R; Call RS; Raoof T; Zhu Z; Yeleswaram S; Gong X; Lee M
Am J Clin Dermatol; 2022 May; 23(3):355-364. PubMed ID: 35368221
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF
J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
[TBL] [Abstract][Full Text] [Related]
7. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.
Bloudek L; Eichenfield LF; Silverberg JI; Joish VN; Lofland JH; Sun K; Augustin M; Migliaccio-Walle K; Sullivan SD
Am J Clin Dermatol; 2023 Jan; 24(1):109-117. PubMed ID: 36264430
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
[No Abstract] [Full Text] [Related]
9. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Forman SB; Kuligowski ME; Kallender H; Sun K; Ren H; Simpson EL
J Am Acad Dermatol; 2023 May; 88(5):1008-1016. PubMed ID: 36574595
[TBL] [Abstract][Full Text] [Related]
10. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
Blauvelt A; Kircik L; Papp KA; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Szepietowski JC
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):137-146. PubMed ID: 36066323
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
[TBL] [Abstract][Full Text] [Related]
12. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
[TBL] [Abstract][Full Text] [Related]
13. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
16. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
